The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

September 29, 2025 updated by: Shuxia Yao, University of Electronic Science and Technology of China

The Modulatory Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), and Adult ADHD Self-Report Scale (ASRS-v1.1). Participants are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before resting state and after the tasks. Three blood samples (5 ml) are collected into 6 ml ETDA tubes when participants just arrive, before resting state recording and after all of the tasks.

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Chengdu
      • Chengdu, Chengdu, China, 611731
        • University of Electronic Science and Technology of China
    • Sichuan
      • Chengdu, Sichuan, China, 611731
        • University of Electronic Science and Technology of China (UESTC)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy subjects without past or current psychiatric or neurological disorders.

Exclusion Criteria:

  • History of head injury.
  • Pregnant,menstruating,taking oral contraceptives.
  • Medical or psychiatric illness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: oxytocin
A single dose of 24 international units (IU) of oxytocin will be administered with 3 puffs of treatment to each nostril.
Drug: Intranasal Oxytocin (IN-OXT)
Subject assigned to receive intranasal administration of oxytocin (24 IU).
Experimental: vasopressin
A single dose of 20 international units (IU) of vasopressin will be administered with 3 puffs of treatment to each nostril.
Drug: Intranasal Vasopressin (AVP)
Subjects assigned to receive intranasal administration of vasopressin (20 IU).
Placebo Comparator: placebo
A single dose of placebo will be administered with 3 puffs of treatment to each nostril.
Drug: Intranasal Placebo
Subjects assigned to receive intranasal administration of placebo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Resting-state EEG
Time Frame: 35-50 minutes after treatment administration.
Participants are asked to sit comfortably and look at a white cross fixation against a black background on the computer monitor for 15 minutes with delta-beta cross-frequency coupling as a main index.
35-50 minutes after treatment administration.
Behavioral indices in the tasks
Time Frame: 50-90 minutes after treatment administration.
Reaction time and accuracy are recorded in the emotional Stroop and Go/Nogo tasks. For the anxiety induction task, participants are instructed to rate their anxiety levels using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very anxious).
50-90 minutes after treatment administration.
Task-based EEG
Time Frame: 50-90 minutes after treatment administration.
EEG data are recorded in the emotional Stroop, Go/Nogo, and anxiety induction tasks. Delta-beta cross-frequency coupling will be calculated to do statistical analyses.
50-90 minutes after treatment administration.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SCR in anxiety induction
Time Frame: 70-90 minutes after treatment administration.
Skin Conductance Response (SCR) data are recorded in the anxiety induction task under safe and anxious conditions.
70-90 minutes after treatment administration.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Electronic Science and Technology of China

Investigators

  • Principal Investigator: Shuxia Yao, Dr, University of Electronic Science and Technology of China

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 2, 2024

Primary Completion (Actual)

July 28, 2025

Study Completion (Actual)

August 12, 2025

Study Registration Dates

First Submitted

September 18, 2024

First Submitted That Met QC Criteria

September 18, 2024

First Posted (Actual)

September 20, 2024

Study Record Updates

Last Update Posted (Estimated)

October 3, 2025

Last Update Submitted That Met QC Criteria

September 29, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UESTC-neuSCAN-96

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Intranasal Oxytocin (IN-OXT)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe